drugset / Trial / NCT02546544
Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
Phase 2
Completed
16 enrolled
University of Oxford
Astellas Pharma Inc · collabEuropean Commission · collabEuropean Organisation for Research and Treatment of Cancer - EORTC · collabOxford University Hospitals NHS Trust · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an international, multi-centre, single arm Bayesian designed phase 2 study to identify and determine the safety and activity of anti-IGF-1/IR inhibition in patients with relapsed and/or refractory ESFT. Approximately 40 patients will be recruited from 5-7 European centres. Each patient will be treated with single agent linsitinib, 600 mg orally once a day for days 1-3, 8-10 and 15-17 on a 21 day cycle until disease progression or undue toxicity.
Timeline
- Start
- 2014-03
- Primary completion
- 2016-07-15
- Completion
- 2016-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | linsitinib | Small molecule | 600 mg | Oral |